NASDAQ:AVEO AVEO Pharmaceuticals - AVEO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AVEO Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $15.00 0.00 (0.00%) (As of 01/19/2023) Add Compare Share Share Today's Range$14.99▼$15.0050-Day Range$14.87▼$15.0052-Week Range$3.06▼$15.00Volume247,800 shsAverage Volume601,442 shsMarket Capitalization$521.45 millionP/E RatioN/ADividend YieldN/APrice Target$15.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media AVEO Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/DownsideN/AShort InterestHealthy2.69% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.35Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.68) to $0.52 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.33 out of 5 starsMedical Sector974th out of 1,027 stocksPharmaceutical Preparations Industry474th out of 500 stocks 1.0 Analyst's Opinion Consensus RatingAVEO Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Amount of Analyst CoverageAVEO Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.69% of the float of AVEO Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAVEO Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AVEO Pharmaceuticals has recently decreased by 14.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAVEO Pharmaceuticals does not currently pay a dividend.Dividend GrowthAVEO Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AVEO. Previous Next 1.9 News and Social Media Coverage News SentimentAVEO Pharmaceuticals has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AVEO Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest5 people have searched for AVEO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AVEO Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.29% of the stock of AVEO Pharmaceuticals is held by insiders.Percentage Held by Institutions49.95% of the stock of AVEO Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AVEO Pharmaceuticals are expected to grow in the coming year, from ($0.68) to $0.52 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AVEO Pharmaceuticals is -17.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AVEO Pharmaceuticals is -17.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAVEO Pharmaceuticals has a P/B Ratio of 11.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About AVEO Pharmaceuticals (NASDAQ:AVEO) StockAVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.Read More Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVEO Stock News HeadlinesFebruary 2, 2023 | americanbankingnews.comAVEO Pharmaceuticals (NASDAQ:AVEO) Receives New Coverage from Analysts at StockNews.comJanuary 31, 2023 | marketwatch.comHepatocyte Growth Factor Market 2023-2029 Global Forecast with Top Key Players such as: ViroMed, AnGes MG, M3 Biotechnology, AVEO PharmaceuticalsFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 24, 2023 | marketwatch.comAdvanced Renal Cell Carcinoma Therapeutics Market Experiences Significant Growth Over the 2023-2028 Timeframe, Credited to Technological AdvancesJanuary 13, 2023 | marketwatch.comCancer Drug Therapy Market Detailed Analysis of Current Industry Figures with Forecasts Regional Outlook 2028January 12, 2023 | marketwatch.comHepatocyte Growth Factor Market 2023 : Growth Statistics, Industry Share, Latest Trends, Growth Drivers, Size and Forecast till 2028January 7, 2023 | msn.comAveo Oncology shareholders approve acquisition by LG ChemJanuary 5, 2023 | finance.yahoo.comAVEO Oncology Stockholders Approve Acquisition by LG ChemFebruary 7, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...November 21, 2022 | finance.yahoo.comAVEO Oncology (AVEO): Strong Industry, Solid Earnings Estimate RevisionsNovember 18, 2022 | finance.yahoo.comInhibrx (INBX) Down on Updated Data From Bone Cancer StudyNovember 16, 2022 | finance.yahoo.comArcutis (ARQT) Up on Top-Line Data From Atopic Dermatitis StudyNovember 14, 2022 | finance.yahoo.comWhat Makes AVEO Pharmaceuticals (AVEO) a Strong Momentum Stock: Buy Now?November 8, 2022 | msn.comWhat 4 Analyst Ratings Have To Say About AVEO PharmaceuticalsNovember 8, 2022 | technews.tmcnet.comAVEO Oncology Reports Third Quarter 2022 Financial ResultsOctober 29, 2022 | markets.businessinsider.comJonesTrading Reaffirms Their Hold Rating on AVEO Pharma (AVEO)October 27, 2022 | finance.yahoo.comAVEO Oncology (AVEO) to Report Q3 Earnings: Is a Beat in Store?October 25, 2022 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AKUS, AVEO, LFG, CLROctober 21, 2022 | finance.yahoo.comAre Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?October 21, 2022 | finance.yahoo.comAre Medical Stocks Lagging AVEO Pharmaceuticals (AVEO) This Year?October 18, 2022 | finance.yahoo.comCancer biotech to be acquired by Korean pharma, 21 years after foundingOctober 18, 2022 | apnews.comGoldman Sachs, Lockheed Martin rise; Hasbro, Conn’s fallOctober 18, 2022 | benzinga.comLooking Into AVEO Pharmaceuticals's Recent Short InterestOctober 18, 2022 | finance.yahoo.comLG Chem to acquire AVEO Oncology for $566 millionOctober 18, 2022 | marketwatch.comLG Chem Expects to Complete $566M Acquisition Deal With AVEO by 1Q 2023October 17, 2022 | finance.yahoo.comZacks.com featured highlights Par Pacific, AVEO Pharmaceuticals and Heritage CommerceOctober 14, 2022 | nasdaq.comDid These 6 Biotech Stocks Catch Your Eye?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AVEO Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AVEO Company Calendar Last Earnings11/08/2021Today2/07/2023Next Earnings (Estimated)3/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:AVEO CUSIP05358810 CIK1325879 Webwww.aveooncology.com Phone(617) 400-0101Fax617-995-4995Employees114Year Founded2001Price Target and Rating Average Stock Price Forecast$15.00 High Stock Price Forecast$15.00 Low Stock Price Forecast$15.00 Forecasted Upside/Downside0.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,340,000.00 Net Margins-30.79% Pretax Margin-30.79% Return on Equity-81.66% Return on Assets-28.83% Debt Debt-to-Equity Ratio0.94 Current Ratio2.37 Quick Ratio2.35 Sales & Book Value Annual Sales$42.29 million Price / Sales12.33 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book11.28Miscellaneous Outstanding Shares34,763,000Free Float33,619,000Market Cap$521.45 million OptionableOptionable Beta1.00 Social Links Key ExecutivesMichael P. BaileyPresident, Chief Executive Officer & DirectorJebediah LedellChief Operating OfficerErick J. LuceraChief Financial OfficerMatthew CoulterVice President-Information TechnologyStefanie SolomonHead-ComplianceKey CompetitorsVanda PharmaceuticalsNASDAQ:VNDALexicon PharmaceuticalsNASDAQ:LXRXEmergent BioSolutionsNYSE:EBSRigel PharmaceuticalsNASDAQ:RIGLIntercept PharmaceuticalsNASDAQ:ICPTView All CompetitorsInsiders & InstitutionsBirchview Capital LPSold 40,000 shares on 2/3/2023Ownership: 0.288%Simplex Trading LLCSold 3,600 shares on 2/2/2023Ownership: 0.000%Wolverine Asset Management LLCBought 20,076 shares on 2/1/2023Ownership: 0.058%Zurcher Kantonalbank Zurich Cantonalbank Bought 6,409 shares on 2/1/2023Ownership: 0.018%Trium Capital LLPBought 122,140 shares on 1/31/2023Ownership: 0.351%View All Institutional Transactions AVEO Stock - Frequently Asked Questions Should I buy or sell AVEO Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last twelve months. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AVEO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVEO, but not buy additional shares or sell existing shares. View AVEO analyst ratings or view top-rated stocks. What is AVEO Pharmaceuticals' stock price forecast for 2023? 5 analysts have issued 1 year price targets for AVEO Pharmaceuticals' stock. Their AVEO share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next year. View analysts price targets for AVEO or view top-rated stocks among Wall Street analysts. How have AVEO shares performed in 2023? AVEO Pharmaceuticals' stock was trading at $14.95 at the start of the year. Since then, AVEO stock has increased by 0.3% and is now trading at $15.00. View the best growth stocks for 2023 here. When is AVEO Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our AVEO earnings forecast. How were AVEO Pharmaceuticals' earnings last quarter? AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. The biopharmaceutical company had revenue of $15.17 million for the quarter, compared to analyst estimates of $14.29 million. AVEO Pharmaceuticals had a negative trailing twelve-month return on equity of 81.66% and a negative net margin of 30.79%. During the same period in the previous year, the company earned ($0.33) earnings per share. When did AVEO Pharmaceuticals' stock split? AVEO Pharmaceuticals shares reverse split on the morning of Thursday, February 20th 2020. The 1-10 reverse split was announced on Wednesday, February 19th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 19th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Tuan Ha-Ngoc's approval rating as AVEO Pharmaceuticals' CEO? 4 employees have rated AVEO Pharmaceuticals Chief Executive Officer Tuan Ha-Ngoc on Glassdoor.com. Tuan Ha-Ngoc has an approval rating of 61% among the company's employees. This puts Tuan Ha-Ngoc in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 48.0% of employees surveyed would recommend working at AVEO Pharmaceuticals to a friend. What other stocks do shareholders of AVEO Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other AVEO Pharmaceuticals investors own include Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), OPKO Health (OPK), Novavax (NVAX), Sorrento Therapeutics (SRNE), Corbus Pharmaceuticals (CRBP), Synergy Pharmaceuticals (SGYP) and NVIDIA (NVDA). What is AVEO Pharmaceuticals' stock symbol? AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO." Who are AVEO Pharmaceuticals' major shareholders? AVEO Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Trium Capital LLP (0.35%), Birchview Capital LP (0.29%), Wolverine Asset Management LLC (0.06%), Zurcher Kantonalbank Zurich Cantonalbank (0.02%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Michael Ferraresso, Michael P Bailey and Peter W Sonsini. View institutional ownership trends. How do I buy shares of AVEO Pharmaceuticals? Shares of AVEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AVEO Pharmaceuticals' stock price today? One share of AVEO stock can currently be purchased for approximately $15.00. How much money does AVEO Pharmaceuticals make? AVEO Pharmaceuticals (NASDAQ:AVEO) has a market capitalization of $521.45 million and generates $42.29 million in revenue each year. The biopharmaceutical company earns $-53,340,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. How many employees does AVEO Pharmaceuticals have? The company employs 114 workers across the globe. How can I contact AVEO Pharmaceuticals? AVEO Pharmaceuticals' mailing address is 30 WINTER STREET, BOSTON MA, 02108. The official website for the company is www.aveooncology.com. The biopharmaceutical company can be reached via phone at (617) 400-0101, via email at ir@aveooncology.com, or via fax at 617-995-4995. This page (NASDAQ:AVEO) was last updated on 2/7/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.